tiprankstipranks
Trending News
More News >
Astec Lifesciences Limited (IN:ASTEC)
:ASTEC
India Market
Advertisement

Astec Lifesciences Limited (ASTEC) AI Stock Analysis

Compare
1 Followers

Top Page

IN:ASTEC

Astec Lifesciences Limited

(ASTEC)

Rating:45Neutral
Price Target:
₹838.00
▼(-1.60% Downside)
Astec Lifesciences Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, profitability, and liquidity issues. Technical analysis shows mixed signals, with some bearish momentum. Valuation metrics further highlight concerns with a negative P/E ratio and no dividend yield, suggesting potential overvaluation.

Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)

Astec Lifesciences Limited Business Overview & Revenue Model

Company DescriptionAstec Lifesciences Limited (ASTEC) is a leading chemical company specializing in the production and distribution of agrochemical active ingredients, intermediates, and pharmaceutical intermediates. Operating within the agricultural and pharmaceutical sectors, the company focuses on providing high-quality products that cater to the needs of crop protection, animal health, and specialty chemicals industries. Astec Lifesciences is committed to innovation and sustainability, leveraging cutting-edge technology to enhance its product offerings and maintain a competitive edge in the market.
How the Company Makes MoneyAstec Lifesciences Limited makes money primarily through the manufacturing and sale of agrochemicals, which include active ingredients and intermediates used in the formulation of herbicides, fungicides, and insecticides. The company's revenue model is centered around supplying these chemicals to both domestic and international markets, serving agricultural companies and distributors. Key revenue streams for Astec include the direct sale of its chemical products, contract manufacturing services, and strategic partnerships or collaborations with other chemical and agricultural companies. These partnerships often enable the company to expand its distribution networks and enhance its market reach. Additionally, Astec's focus on research and development allows it to innovate and introduce new products, which can lead to increased sales and market share.

Astec Lifesciences Limited Financial Statement Overview

Summary
Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.
Income Statement
35
Negative
The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.
Balance Sheet
45
Neutral
The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.
Cash Flow
30
Negative
The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.81B3.81B4.58B6.28B6.77B5.55B
Gross Profit324.69M843.67M1.33B2.27B2.86B2.10B
EBITDA-620.17M-662.07M-2.69M893.14M1.65B1.19B
Net Income-1.35B-1.35B-469.30M255.65M898.59M650.49M
Balance Sheet
Total Assets8.81B8.81B9.75B9.79B8.97B6.78B
Cash, Cash Equivalents and Short-Term Investments27.05M27.05M16.47M27.54M33.44M15.42M
Total Debt5.55B5.55B4.94B3.41B2.79B1.87B
Total Liabilities6.46B6.46B6.05B5.60B5.00B3.68B
Stockholders Equity2.35B2.35B3.69B4.19B3.96B3.09B
Cash Flow
Free Cash Flow0.00-302.20M-1.25B-426.03M-803.74M-1.11B
Operating Cash Flow0.00-83.99M102.21M746.56M236.04M-81.62M
Investing Cash Flow0.00-152.30M-1.35B-1.13B-1.04B-731.10M
Financing Cash Flow0.00237.33M1.25B377.70M804.77M813.36M

Astec Lifesciences Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price851.65
Price Trends
50DMA
877.83
Negative
100DMA
797.65
Positive
200DMA
861.23
Negative
Market Momentum
MACD
0.05
Negative
RSI
49.58
Neutral
STOCH
49.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Neutral. The current price of 851.65 is above the 20-day moving average (MA) of 840.53, below the 50-day MA of 877.83, and below the 200-day MA of 861.23, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 49.58 is Neutral, neither overbought nor oversold. The STOCH value of 49.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
₹13.23B21.80
2.25%-1.78%56.00%
61
Neutral
$10.24B6.180.71%2.90%3.45%-36.02%
60
Neutral
₹26.64B25.36
0.86%2.73%-11.40%
56
Neutral
₹14.13B30.99
0.26%9.24%2.10%
52
Neutral
₹14.10B459.40
0.36%
45
Neutral
₹19.53B
0.16%4.76%-63.21%
₹10.81B3,871.25
0.32%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ASTEC
Astec Lifesciences Limited
851.65
-342.00
-28.65%
IN:HERANBA
Heranba Industries Limited
348.45
-144.95
-29.38%
IN:IGPL
IG Petrochemicals Ltd.
437.60
-211.80
-32.61%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
101.34
10.07
11.03%
IN:PUNJABCHEM
Punjab Chemicals & Crop Protection Ltd.
1,165.60
-131.36
-10.13%
IN:UNIENTER
Uniphos Enterprises Limited
155.30
-30.27
-16.31%

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Expands Equity Through Successful Rights Issue
Jul 29, 2025

Astec LifeSciences Limited announced the outcome of its Rights Issue Committee meeting held on July 29, 2025, where they approved the allotment of 26,69,951 equity shares on a rights basis to eligible shareholders at a price of ₹890 per share. This move increases the company’s paid-up equity share capital from 1,96,11,710 to 2,22,81,661 shares, potentially strengthening its financial position and market standing.

Astec LifeSciences Releases Q2 2025 Financial Results
Jul 29, 2025

Astec LifeSciences Limited has published its unaudited financial results for the quarter ending June 30, 2025, as approved by its Board of Directors. The results were announced through newspaper advertisements in Business Standard and Mumbai Lakshdeep, reflecting the company’s commitment to transparency and regulatory compliance.

Astec LifeSciences Limited Concludes 31st AGM with Key Resolutions
Jul 28, 2025

Astec LifeSciences Limited held its 31st Annual General Meeting (AGM) on July 28, 2025, via video conferencing, where key business matters were addressed. The meeting included the presentation of financial statements and audit reports, and shareholders were provided with electronic voting facilities. The results of the voting will be announced within two working days and made available on the company’s website, reflecting the company’s commitment to transparency and stakeholder engagement.

Astec LifeSciences Appoints New Secretarial Auditors for Five-Year Term
Jul 28, 2025

Astec LifeSciences Limited has announced the appointment of M/s. BNP & Associates as the secretarial auditors for a five-year term starting from the financial year 2025-26. This decision, approved at the company’s 31st Annual General Meeting, is expected to enhance the company’s compliance and governance standards, potentially strengthening its market position and stakeholder confidence.

Astec LifeSciences Reports Q2 2025 Financial Results
Jul 28, 2025

Astec LifeSciences Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on July 28, 2025. The results, which were reviewed by the statutory auditors and received an unmodified opinion, reflect the company’s adherence to Indian Accounting Standards (IND AS) and demonstrate its commitment to transparency and regulatory compliance. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance for the specified period.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025